Company Information & Drug Savings for ImmunoGen Medications

ImmunoGen, now part of AbbVie, pioneered antibody-drug conjugate (ADC) technology for cancer treatment. The company developed Elahere (mirvetuximab soravtansine), an ADC targeting folate receptor alpha for platinum-resistant ovarian cancer. ImmunoGen’s ADC platform enables targeted delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissue.